Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Using computational models, the researchers studied how the brain's reward-learning system functions in those with depression, especially among individuals experiencing anhedonia, the inability to ...